StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Monday morning. The firm issued a sell rating on the stock.

NSPR has been the topic of a number of other reports. Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Up 0.4 %

Shares of NSPR opened at $2.68 on Monday. The company has a 50-day simple moving average of $2.78 and a 200-day simple moving average of $2.71. The company has a market capitalization of $69.91 million, a PE ratio of -3.57 and a beta of 0.99. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the prior year, the company earned ($0.15) EPS. On average, research analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC purchased a new position in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD at the end of the most recent quarter. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.